2026-04-17T17:18:17Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/84202024-12-13T09:43:25Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Pala Vila, Elena author Bustamante Rangel, Alejandro author Clua-Espuny, Jose L. author Acosta, Juan author Gonzalez-Loyola, Felipe author Dos Santos, Sara author Penalba Morenilla, Anna author Montaner Villalonga, Joan author Giralt Arnaiz, Marina author 2022-11-09T08:13:01Z 2022-11-09T08:13:01Z 2022-08-23 Biomarkers; Electrocardiography; Blood plasma Biomarcadores; Electrocardiografía; Plasma sanguíneo Biomarcadors; Electrocardiografia; Plasma sanguini Background and objective AFRICAT is a prospective cohort study intending to develop an atrial fibrillation (AF) screening program through the combination of blood markers, rhythm detection devices, and long-term monitoring in our community. In particular, we aimed to validate the use of NT-proBNP, and identify new blood biomarkers associated with AF. Also, we aimed to compare AF detection using various wearables and long-term Holter monitoring. Methods 359 subjects aged 65–75 years with hypertension and diabetes were included in two phases: Phase I (n = 100) and Phase II (n = 259). AF diagnosis was performed by baseline 12-lead ECG, 4 weeks of Holter monitoring (NuuboTM), and/or medical history. An aptamer array including 1310 proteins was measured in the blood of 26 patients. Candidates were selected according to p-value, logFC and biological function to be tested in verification and validation phases. Several screening devices were tested and compared: AliveCor, Watch BP, MyDiagnostick and Fibricheck. Results AF was present in 34 subjects (9.47%). The aptamer array revealed 41 proteins with differential expression in AF individuals. TIMP-2 and ST-2 were the most promising candidates in the verification analysis, but none of them was further validated. NT-proBNP (log-transformed) (OR = 1.934; p<0.001) was the only independent biomarker to detect AF in the whole cohort. Compared to an ECG, WatchBP had the highest sensitivity (84.6%) and AUC (0.895 [0.780–1]), while MyDiagnostick showed the highest specificity (97.10%). Conclusion The inclusion and monitoring of a cohort of primary care patients for AF detection, together with the testing of biomarkers and screening devices provided useful lessons about AF screening in our community. An AF screening strategy using rhythm detection devices and short monitoring periods among high-risk patients with high NT-proBNP levels could be feasible. This work was supported by Fundació Marató de TV3 in the research call “La Marató 2014: malalties del cor” [grant number: 201528-30-31-3]. EP received a predoctoral grant from Vall d’Hebron Institute of Research. Neurovascular Research Laboratory also takes part in the Span-ish stroke research network INVICTUS+ [RD16/0019]. This project is supported by AFFECT-EU, receiving funding from the European Union’s Horizon 2020 research and innovation pro-gramme under grant agreement N°847770. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. http://hdl.handle.net/11351/8420 Marcadors bioquímics Fibril·lació auricular Electrocardiografia DISEASES::Cardiovascular Diseases::Heart Diseases::Arrhythmias, Cardiac::Atrial Fibrillation CHEMICALS AND DRUGS::Biological Factors::Biomarkers ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques, Cardiovascular::Heart Function Tests::Electrocardiography::Electrocardiography, Ambulatory ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::arritmias cardíacas::fibrilación atrial COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::técnicas diagnósticas cardiovasculares::pruebas de función cardíaca::electrocardiografía::electrocardiografía ambulatoria Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study